Pricing Report Sales San Diego 
Xconomy
MARCH 1, 2019
biopharmaceutical industry is dealing with unprecedented threats on several fronts: public backlash against high drug prices, slowing sales, and the possibility of more government regulation. In this Report, you’ll learn: The key indicators that suggest a possible downturn is on the way. After years of boom times, the U.S.
Xconomy
MAY 10, 2019
An April report from Evaluate Pharma predicted sales of orphan drugs to rise 12 percent a year between now and 2024, when they will account for an estimated 20 percent of worldwide prescription drug sales. The market for drugs for rare or “orphan” diseases continues to grow.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
NOVEMBER 10, 2016
There is no mention of drug pricing or what the administration might do about frequent price increases, such as Mylan’s EpiPen practice, that critics say are unsubstantiated and unethical. It doesn’t necessarily allude to drug-price negotiation. In fact, the 2003 law signed by President George W.
Xconomy
JULY 7, 2016
Morristown, NJ-based Pernix (NASDAQ: PTX ) will cut 60 workers , mostly from its neurology sales staff, the company said today. As of the end of 2015, Pernix reported a headcount of 274. In 2014, Pernix, then based in The Woodlands, TX, acquired San Diego-based Somaxon Pharmaceuticals. Last year, Pernix reported a $148.3
socalTECH
DECEMBER 1, 2011
San Diego-based Active Network reported this morning that its RTP unit, the provider of ski resort and park information software, has launched a new mobile app platform called LiveInfo. Pricing on the new tool was not announced by RTP and Active Network. Active Network acquired RTP on November 10th.
Xconomy
OCTOBER 5, 2018
But since then its stock price has fallen significantly, dropping below $1 per share multiple times in the past two years, which nearly got the listing booted from the Nasdaq exchange. subsidiary, Firmenich—which reported about $3.3 billion in sales in 2017—said Thursday it had had agreed to buy Senomyx for $1.50
Xconomy
JULY 1, 2016
At the gathering, Biden took verbal shots at scofflaw cancer researchers and at drug prices, while the FDA said it would take a shot at restructuring the way it evaluates oncology products. Gilead Sciences has been a target of drug-price criticism for its hepatitis C treatments, but it dialed back the price of its new one.
Expert insights. Personalized for you.
83 
Let's personalize your content